Stock DNA
Pharmaceuticals & Biotechnology
GBP 136 Million ()
NA (Loss Making)
NA
0.00%
0.21
-5.34%
0.45
Revenue and Profits:
Net Sales:
23 Million
(Quarterly Results - Mar 2025)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.43%
0%
-2.43%
6 Months
-21.81%
0%
-21.81%
1 Year
-44.88%
0%
-44.88%
2 Years
-46.87%
0%
-46.87%
3 Years
-48.72%
0%
-48.72%
4 Years
-62.47%
0%
-62.47%
5 Years
-46.22%
0%
-46.22%
Benchmark Holdings Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.06%
EBIT Growth (5y)
8.71%
EBIT to Interest (avg)
-0.47
Debt to EBITDA (avg)
2.04
Net Debt to Equity (avg)
-0.42
Sales to Capital Employed (avg)
0.39
Tax Ratio
5.80%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.45
EV to EBIT
-1.52
EV to EBITDA
0.54
EV to Capital Employed
0.06
EV to Sales
0.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.63%
ROE (Latest)
-5.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
22.90
17.70
29.38%
Operating Profit (PBDIT) excl Other Income
4.40
-0.20
2,300.00%
Interest
2.50
2.30
8.70%
Exceptional Items
-2.50
-1.70
-47.06%
Consolidate Net Profit
-5.80
-7.30
20.55%
Operating Profit Margin (Excl OI)
8.60%
-252.20%
26.08%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is 29.38% vs -42.35% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 20.55% vs 26.26% in Dec 2024
Annual Results Snapshot (Consolidated) - Sep'24
Sep'24
Sep'23
Change(%)
Net Sales
90.40
104.00
-13.08%
Operating Profit (PBDIT) excl Other Income
11.90
17.00
-30.00%
Interest
9.00
8.80
2.27%
Exceptional Items
-6.10
-1.90
-221.05%
Consolidate Net Profit
-44.30
-23.50
-88.51%
Operating Profit Margin (Excl OI)
-331.10%
-131.10%
-20.00%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2024 is -13.08% vs -34.05% in Sep 2023
Consolidated Net Profit
YoY Growth in year ended Sep 2024 is -88.51% vs 18.12% in Sep 2023
About Benchmark Holdings Plc 
Benchmark Holdings Plc
Pharmaceuticals & Biotechnology
Benchmark Holdings plc is engaged in the provision of aquaculture health, genetics and nutrition. The Company’s segments include genetics, advanced nutrition and health. The Company develops products that helps fish and shrimp to improve their sustainability and profitability by improving yield, quality, and by reducing mortality. The Company’s products include high genetic quality ova for salmon, shrimp and tilapia, and breeding, program, specialist feeds for early stage shrimp and fish; probiotics, biocides and medicines.
Company Coordinates 
Company Details
Benchmark House, 8 Smithy Wood Drive , SHEFFIELD None : S35 1QN
Registrar Details






